US 12,264,160 B2
Pharmaceutical compositions comprising 4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one for treating central nervous system disorders
Peng Li, New Milford, NJ (US); Qiang Zhang, Plainsboro, NJ (US); Robert Davis, San Diego, CA (US); and Lawrence P. Wennogle, Steamboat Springs, CO (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
Filed on Jun. 1, 2023, as Appl. No. 18/327,607.
Application 17/072,933 is a division of application No. 16/591,178, filed on Oct. 2, 2019, granted, now 10,844,061, issued on Nov. 24, 2020.
Application 18/327,607 is a continuation of application No. 18/314,785, filed on May 9, 2023.
Application 18/314,785 is a continuation of application No. 17/072,933, filed on Oct. 16, 2020, granted, now 11,680,065.
Application 16/591,178 is a continuation of application No. 16/056,143, filed on Aug. 6, 2018, granted, now 10,472,359, issued on Nov. 12, 2019.
Application 16/056,143 is a continuation of application No. 15/629,481, filed on Jun. 21, 2017, granted, now 10,072,010, issued on Sep. 11, 2018.
Application 15/629,481 is a continuation of application No. 14/777,466, granted, now 9,708,322, issued on Jul. 18, 2017, previously published as PCT/US2014/029914, filed on Mar. 15, 2014.
Claims priority of provisional application 61/799,405, filed on Mar. 15, 2013.
Prior Publication US 2023/0339951 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/437 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 31/4985 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01); C07D 471/14 (2006.01); C07D 471/16 (2006.01); C07D 471/22 (2006.01)
CPC C07D 471/16 (2013.01) [A61K 9/4825 (2013.01); A61K 9/4891 (2013.01); A61K 9/5031 (2013.01); A61K 31/4985 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); C07D 471/14 (2013.01)] 28 Claims
 
1. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier in admixture with:
(i) a compound of Formula Q:

OG Complex Work Unit Chemistry
wherein:
W is —N(CH3)—; and
Y is —C(O)—;
in free base or pharmaceutically acceptable salt form; and
(ii) a polymeric matrix;
wherein:
(a) the compound of Formula Q is dissolved or dispersed in the pharmaceutical composition;
(b) the pharmaceutical composition is formulated as a sustained-release injectable composition or a delayed-release injectable composition;
(c) wherein the pharmaceutically acceptable diluent or carrier is an organic solvent; and
(d) wherein the pharmaceutical composition is non-aqueous.